Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Daily News

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

Shelley Wood

December 22, 2021

News Conference News TCT 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

Caitlin E. Cox

November 06, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

Todd Neale

October 14, 2021

Podcast TCTMD Talking Points

The TICO-STEMI Trial

October 06, 2021

News Daily News

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

Michael O'Riordan

October 04, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

Shelley Wood

October 01, 2021

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

News Conference News ESC 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

Caitlin E. Cox

August 31, 2021

Presentation ESC 2021

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Presenter: Hirotoshi Watanabe

August 31, 2021

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

Shelley Wood

August 30, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Daily News

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

Yael L. Maxwell

July 16, 2021

News Conference News EAS 2021

Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI

Michael O'Riordan

June 07, 2021

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2021

Shelley Wood

May 31, 2021

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

L.A. McKeown

May 21, 2021

Advertisement

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Half-Dose DOAC May Be a Good Post-Watchman Option

The TICO-STEMI Trial

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

TCTMD’s Top 10 Most Popular Stories for September 2021

Heterozygous FH Diagnosed Late, Remains Undertreated

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

TCTMD’s Top 10 Most Popular Stories for May 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content